Dual inhibition of PI3K and MAPK pathway has shown benefit in a genetically engineered mouse model of imatinib-resistant GIST equivalent to ex 11 with T670I mutation of human KIT protein. This evidence concerns the gene KIT and gastrointestinal stromal tumor.